Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Chloride Channel Activator [EPC]
Lubiprostone is a specialized chloride channel activator used to treat chronic idiopathic constipation, opioid-induced constipation, and irritable bowel syndrome with constipation (IBS-C) in women by increasing intestinal fluid secretion.
Name
Lubiprostone
Raw Name
LUBIPROSTONE
Category
Chloride Channel Activator [EPC]
Drug Count
3
Variant Count
41
Last Verified
February 17, 2026
RxCUI
616578, 794639, 617768, 794641
UNII
7662KG2R6K
About Lubiprostone
Lubiprostone is a specialized chloride channel activator used to treat chronic idiopathic constipation, opioid-induced constipation, and irritable bowel syndrome with constipation (IBS-C) in women by increasing intestinal fluid secretion.
Detailed information about Lubiprostone
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Lubiprostone.
Lubiprostone is a locally acting, bicyclic fatty acid derivative that belongs to a unique pharmacological class known as chloride channel activators [EPC]. Unlike traditional laxatives that may rely on osmotic pressure (drawing water into the gut) or direct stimulation of the enteric nervous system, Lubiprostone functions by specifically targeting and activating Type-2 Chloride Channels (ClC-2) located in the apical (luminal) membrane of the human intestinal epithelium. By activating these specific channels, the drug promotes the secretion of chloride-rich intestinal fluid into the lumen, which in turn facilitates the passive movement of sodium and water into the bowel. This process increases the liquidity of the intestinal contents, enhances intestinal motility, and eases the passage of stool, thereby alleviating the symptoms associated with chronic constipation and irritable bowel syndrome.
Lubiprostone was first approved by the U.S. Food and Drug Administration (FDA) in 2006 under the brand name Amitiza. It represented a significant advancement in the management of gastrointestinal disorders because it bypassed the systemic side effects often associated with other prokinetic agents. It is currently indicated for the treatment of Chronic Idiopathic Constipation (CIC) in adults, Opioid-Induced Constipation (OIC) in adult patients with chronic non-cancer pain (including those with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation), and Irritable Bowel Syndrome with Constipation (IBS-C) specifically in adult women.
To understand how Lubiprostone works, one must first understand the physiology of intestinal fluid balance. In a healthy digestive tract, the movement of water into the intestine is driven by the active transport of ions, primarily chloride. Lubiprostone acts as a selective activator of the ClC-2 chloride channel. This channel is a protein that forms a pore across the cell membrane, allowing chloride ions to flow out of the epithelial cells and into the intestinal lumen.
When Lubiprostone binds to these channels, it triggers a 'pro-secretory' effect. As chloride ions enter the intestine, they create an electrochemical gradient that pulls sodium ions and water along with them. This increase in intestinal fluid does two things: first, it softens the stool, making it easier to pass; second, it increases the volume of the intestinal contents, which physically stretches the intestinal wall and triggers natural peristaltic waves (the muscular contractions that move waste through the gut). Because Lubiprostone acts locally on the inner lining of the intestine and has very low systemic absorption, its primary effects are localized to the gastrointestinal tract, which helps limit its impact on other organ systems. It is important to note that Lubiprostone does not appear to affect the serum concentrations of sodium or potassium, maintaining electrolyte balance while improving bowel function.
Lubiprostone is characterized by very low systemic bioavailability. In fact, following oral administration, plasma concentrations of the parent drug are typically below the level of quantitation (less than 10 pg/mL). Because the drug acts locally within the lumen of the stomach and small intestine, its clinical efficacy is not dependent on reaching high levels in the bloodstream. However, its primary active metabolite, known as M3 (a reduced ketone metabolite), is measurable in the plasma. When taken with a high-fat meal, the peak plasma concentration (Cmax) of M3 is slightly decreased, although the overall extent of absorption (AUC) remains relatively stable. Taking the medication with food is clinically recommended primarily to mitigate the common side effect of nausea.
Due to the rapid local metabolism and low systemic levels of the parent drug, distribution studies in humans are limited. However, in vitro data suggest that the active metabolite M3 is approximately 94% bound to human plasma proteins. It does not appear to cross the blood-brain barrier in significant amounts, which contributes to its lack of central nervous system effects.
Lubiprostone undergoes rapid and extensive metabolism, primarily within the stomach and the jejunum (the middle segment of the small intestine). This metabolism is mediated by the enzyme carbonyl reductase and does not involve the cytochrome P450 (CYP) isoenzyme system. The primary metabolite, M3, is formed by the reduction of the 15-ketone group. Because the CYP450 system is not involved, Lubiprostone has a lower risk for the traditional drug-drug interactions seen with many other systemic medications.
The active metabolite M3 has a relatively short half-life, ranging from approximately 0.9 to 1.4 hours. Elimination occurs primarily through the urine (about 60% within 24 hours) and the feces (about 30% within 168 hours). Despite renal excretion of the metabolites, the parent drug's local action means that the drug's primary effect is finished once it passes through the small intestine.
Lubiprostone is FDA-approved for three primary indications:
Lubiprostone is available exclusively as an oral gelatin capsule. It is typically found in two strengths:
> Important: Only your healthcare provider can determine if Lubiprostone is right for your specific condition. A thorough evaluation of your gastrointestinal health is necessary before starting this medication.
The dosage of Lubiprostone is highly dependent on the specific condition being treated. Healthcare providers will typically prescribe the following standard regimens:
Clinical response should be monitored periodically. If the patient experiences severe diarrhea or significant nausea, the healthcare provider may suggest a temporary interruption of therapy or a dose reduction.
Lubiprostone is currently not approved for use in pediatric patients. Clinical trials involving children with functional constipation failed to demonstrate a significant benefit over placebo. Furthermore, the safety profile in children has not been as extensively established as it has in adults. Parents and caregivers should consult a pediatric gastroenterologist for alternative treatments for childhood constipation.
No dosage adjustment is required for patients with renal impairment (kidney disease). Because the drug acts locally and its metabolites are not known to be toxic to the kidneys, standard dosing is generally considered safe regardless of the glomerular filtration rate (GFR).
For patients with significant liver disease, the metabolism of the M3 metabolite may be slowed, leading to higher systemic exposure.
In clinical trials, no overall differences in safety or effectiveness were observed between patients over age 65 and younger patients. Therefore, no specific dose adjustments are required for the elderly, provided liver function is adequate.
To ensure maximum efficacy and minimize side effects, Lubiprostone should be taken according to these specific instructions:
If you miss a dose of Lubiprostone, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and return to your regular dosing schedule. Do not take two doses at once to make up for a missed one, as this significantly increases the risk of severe nausea and diarrhea.
Signs of a Lubiprostone overdose may include severe nausea, vomiting, diarrhea, abdominal cramping, and potentially fainting (syncope) due to dehydration or a vasovagal response. In the event of an overdose, seek emergency medical attention or contact a Poison Control Center immediately. Treatment is primarily supportive, focusing on rehydration and the management of gastrointestinal symptoms.
> Important: Follow your healthcare provider's dosing instructions precisely. Do not adjust your dose or stop the medication without medical guidance, as your symptoms may return or worsen.
Lubiprostone is generally well-tolerated, but because of its mechanism of action, gastrointestinal side effects are frequent.
> Warning: Stop taking Lubiprostone and call your doctor immediately if you experience any of the following serious symptoms:
Lubiprostone has been studied in long-term open-label trials for up to 52 weeks. Most evidence suggests that the drug does not cause 'lazy bowel' or dependency, which are concerns with stimulant laxatives. However, long-term use requires monitoring for electrolyte balance, particularly in older adults or those with underlying kidney issues. There is no evidence that Lubiprostone increases the risk of colorectal cancer or other structural changes to the colon.
No FDA black box warnings for Lubiprostone. However, the FDA does emphasize the importance of ruling out mechanical bowel obstruction before initiating therapy.
Report any unusual symptoms or changes in your bowel habits to your healthcare provider. Keeping a 'stool diary' can be helpful for your doctor to assess how well the medication is working and whether the side effects are manageable.
Lubiprostone is a potent medication that alters intestinal fluid dynamics. It is intended only for the specific conditions for which it is prescribed. Patients should be aware that while it is effective, it requires careful monitoring of gastrointestinal symptoms. It is not a 'rescue' laxative for occasional constipation but rather a maintenance therapy for chronic conditions.
There are currently no FDA black box warnings for Lubiprostone. It is considered to have a favorable safety profile when used as directed for its approved indications.
Before starting Lubiprostone, your healthcare provider must perform a thorough examination to ensure you do not have a mechanical bowel obstruction. Taking a pro-secretory agent in the presence of a physical blockage can lead to severe abdominal pain, vomiting, and potential bowel perforation. If you have symptoms such as severe bloating, inability to pass gas, and intense vomiting, do not take Lubiprostone.
Patients should be aware of the risk of severe diarrhea. If diarrhea occurs, the patient should stop taking Lubiprostone and contact their healthcare provider. The risk is higher in older patients and those taking other medications that can cause diarrhea. Rehydration is the primary treatment for medication-induced diarrhea.
In clinical trials, approximately 3% to 6% of patients reported a sensation of shortness of breath. This is thought to be related to the drug's effect on certain prostaglandin receptors in the lungs or chest wall. It is generally not associated with actual changes in oxygen levels or lung function, but it can be frightening. It usually happens with the first dose and resolves on its own, but it should always be reported to a doctor.
While rare, hypersensitivity reactions can occur. Patients with a known allergy to Lubiprostone or any of the inactive ingredients in the capsule (such as gelatin or sorbitol) should not take the medication.
There are no specific laboratory tests (like blood draws) required specifically for Lubiprostone. However, healthcare providers will typically monitor:
Lubiprostone is generally not expected to affect your ability to drive or operate machinery. However, if you experience dizziness or syncope (fainting) as a side effect, you should avoid these activities until you know how the medication affects you.
There is no known direct interaction between Lubiprostone and alcohol. However, alcohol can irritate the gastrointestinal tract and may worsen symptoms like nausea, diarrhea, or abdominal pain. It is generally advisable to limit alcohol consumption while treating chronic gastrointestinal disorders.
Lubiprostone does not require a tapering period. You can stop taking it suddenly without experiencing a 'withdrawal syndrome.' However, your original symptoms of constipation or IBS-C are likely to return once the medication is stopped. Always discuss stopping a long-term medication with your doctor first.
> Important: Discuss all your medical conditions, especially any history of bowel blockages or liver disease, with your healthcare provider before starting Lubiprostone.
There are no medications that are strictly contraindicated for use with Lubiprostone based on metabolic interactions, as Lubiprostone is not metabolized by the cytochrome P450 system. However, it should not be used in patients with a known mechanical gastrointestinal obstruction, which is a clinical contraindication rather than a drug-drug interaction.
Some clinical data suggest that diphenylheptane opioids like methadone may interfere with the activation of ClC-2 chloride channels. This could potentially reduce the effectiveness of Lubiprostone in treating opioid-induced constipation. If you are taking methadone for pain management or addiction recovery, your doctor may need to monitor your response to Lubiprostone more closely and consider alternative treatments if bowel movements do not improve.
Drugs with anticholinergic properties (such as diphenhydramine, benztropine, or certain antidepressants) work by slowing down the movement of the gut. Since Lubiprostone is intended to increase motility and secretion, these drugs may work against each other. While not dangerous, the combination may result in Lubiprostone being less effective than expected.
Taking Lubiprostone with other stimulant laxatives (like bisacodyl or senna) or osmotic laxatives (like polyethylene glycol) may increase the risk of severe diarrhea and electrolyte depletion. These combinations should only be used under the direct supervision of a healthcare provider.
As noted in the pharmacology section, high-fat meals can slightly alter the peak concentration of the active metabolite. However, this is not considered clinically significant for the drug's efficacy. More importantly, taking Lubiprostone with food is strongly recommended to reduce the risk of nausea. There are no specific restrictions on dairy, grapefruit, or caffeine, though caffeine may worsen diarrhea in some sensitive individuals.
Many patients take magnesium for constipation. Since magnesium also acts as an osmotic laxative, taking it with Lubiprostone may increase the frequency of loose stools.
Because Lubiprostone is not metabolized by the CYP3A4 enzyme, St. John's Wort is not expected to affect its levels in the body, unlike many other medications.
Lubiprostone is not known to interfere with common laboratory tests, including blood chemistry, hematology, or urinalysis. It does not affect the results of fecal occult blood tests.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking to ensure the safest and most effective treatment plan.
Lubiprostone must NEVER be used in the following circumstances:
These are conditions where the risks and benefits must be carefully weighed by a healthcare professional:
There is no documented cross-sensitivity between Lubiprostone and other classes of laxatives or prokinetic agents (like linaclotide or prucalopride). However, because Lubiprostone is a prostaglandin E1 derivative, patients who have had severe reactions to other prostaglandins (such as misoprostol) should use Lubiprostone with extreme caution and under close medical supervision.
> Important: Your healthcare provider will evaluate your complete medical history, including any history of abdominal surgeries or inflammatory bowel disease, before prescribing Lubiprostone. If you experience sudden, intense abdominal pain while taking this medication, stop use and seek immediate medical help.
Lubiprostone is classified as a medication that should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. In animal studies, high doses of Lubiprostone were associated with an increased risk of fetal loss. Because Lubiprostone is a synthetic derivative of prostaglandin E1, and prostaglandins are known to involve uterine contractions, there is a theoretical risk of inducing labor or miscarriage. However, systemic exposure to Lubiprostone in humans is extremely low. Women of childbearing age should discuss the risks with their doctor, and a pregnancy test may be recommended before starting treatment if pregnancy is suspected.
It is not known whether Lubiprostone is excreted in human milk. However, because the drug has very low systemic absorption, the amount that could potentially reach a nursing infant is likely to be negligible. The primary concern for a breastfeeding infant would be the development of diarrhea. Nursing mothers taking Lubiprostone should monitor their infants for any changes in stool consistency. Decisions regarding breastfeeding while on Lubiprostone should be made in consultation with a pediatrician.
Lubiprostone is not approved for use in children. Clinical trials in pediatric populations (ages 6 to 17) for functional constipation did not show that the drug was more effective than a placebo. Furthermore, safety in children under the age of 6 has not been evaluated at all. The use of this drug in pediatric populations is generally discouraged unless directed by a specialist in a research setting.
In clinical studies, approximately 16% of patients were 65 years of age or older. No overall differences in the safety or effectiveness of Lubiprostone were observed between these elderly patients and younger subjects. However, elderly patients are more susceptible to dehydration from diarrhea. Therefore, healthcare providers should monitor hydration status and electrolyte levels more closely in the geriatric population.
No dosage adjustment is necessary for patients with impaired renal function. The local action of the drug in the GI tract means that its primary therapeutic effect is independent of kidney function. Clinical trials included patients with varying degrees of renal impairment, and no significant safety concerns were identified.
Patients with moderate to severe liver disease (Child-Pugh Class B or C) require dose adjustments. The liver is involved in the clearance of the M3 metabolite. In patients with severe hepatic impairment, the systemic exposure to the M3 metabolite can be significantly increased, which may increase the risk of side effects like nausea and dyspnea.
> Important: Special populations require individualized medical assessment to ensure that the benefits of Lubiprostone outweigh any potential risks associated with their specific physiological state.
Lubiprostone is a selective Type-2 Chloride Channel (ClC-2) activator. Unlike other laxatives, it does not rely on osmotic gradients or direct nerve stimulation. Instead, it binds to the ClC-2 channels on the apical membrane of intestinal epithelial cells. This binding causes the channels to open, allowing chloride ions to flow into the intestinal lumen. To maintain electrical neutrality, sodium ions follow the chloride, and water follows the sodium via osmosis. This results in an increase in isotonic intestinal fluid secretion, which softens the stool and promotes motility.
The effects of Lubiprostone are primarily local and occur within the gastrointestinal tract. The increase in fluid secretion helps to overcome the slowed transit time seen in chronic constipation. Studies have shown that Lubiprostone increases the frequency of spontaneous bowel movements (SBMs) within 24 to 48 hours of the first dose. There is no evidence of the development of tolerance (where the drug becomes less effective over time) with long-term use.
| Parameter | Value |
|---|---|
| Bioavailability | Extremely Low (Parent drug often undetectable) |
| Protein Binding | ~94% (Active metabolite M3) |
| Half-life | 0.9 to 1.4 hours (Active metabolite M3) |
| Tmax | ~1.1 hours (Active metabolite M3) |
| Metabolism | Carbonyl Reductase (Local and Systemic) |
| Excretion | Renal 60%, Fecal 30% (as metabolites) |
Lubiprostone is the founding member of the Chloride Channel Activator class of medications. It is distinct from Guanylate Cyclase-C (GC-C) agonists like linaclotide and plecanatide, although both classes ultimately increase intestinal fluid secretion. It is also distinct from 5-HT4 receptor agonists like prucalopride, which primarily stimulate muscle contractions (prokinetics).
Medications containing this ingredient
Common questions about Lubiprostone
Lubiprostone is a prescription medication primarily used to treat three specific gastrointestinal conditions in adults. It is FDA-approved for Chronic Idiopathic Constipation (CIC), which is long-term constipation with no known cause. It is also used for Opioid-Induced Constipation (OIC) in adults with chronic non-cancer pain, helping to reverse the constipating effects of pain medications. Additionally, it is approved for the treatment of Irritable Bowel Syndrome with Constipation (IBS-C) specifically in adult women. By increasing fluid secretion in the gut, it helps soften stool and increase the frequency of bowel movements.
The most frequently reported side effect of Lubiprostone is nausea, which affects nearly one-third of patients in some clinical studies. This nausea is usually mild to moderate and is best managed by taking the capsule with a full meal and plenty of water. Diarrhea is the second most common side effect, resulting from the drug's intended effect of increasing intestinal fluid. Other common issues include headaches, abdominal pain, bloating, and gas. Most of these side effects occur early in treatment and may diminish as the body adjusts to the medication.
There is no direct chemical interaction between alcohol and Lubiprostone that makes the combination strictly prohibited. However, alcohol is a known gastrointestinal irritant and can cause both dehydration and changes in bowel motility. Drinking alcohol while taking Lubiprostone may worsen common side effects like nausea, dizziness, or diarrhea. For patients managing chronic constipation or IBS-C, it is generally recommended to limit alcohol intake to help maintain stable gut health. Always consult your doctor about your specific alcohol consumption habits.
Lubiprostone is generally not recommended during pregnancy unless the benefits clearly outweigh the potential risks. Because it is a prostaglandin derivative, there are theoretical concerns that it could affect uterine contractions or fetal development. Animal studies have shown some evidence of fetal loss at very high doses, although human data is limited. If you are pregnant or planning to become pregnant, you must discuss alternative treatments for constipation with your healthcare provider. They will perform a risk-benefit analysis based on the severity of your condition.
Most patients begin to see an improvement in their bowel habits within the first 24 to 48 hours of starting Lubiprostone. In clinical trials, a significant number of patients experienced their first spontaneous bowel movement within 24 hours of the initial dose. However, the full therapeutic benefit for conditions like IBS-C may take several weeks of consistent use. It is important to take the medication exactly as prescribed, usually twice daily, to maintain the pro-secretory effect in the intestines. If you do not see improvement after several days, contact your doctor.
Yes, you can stop taking Lubiprostone without the risk of withdrawal symptoms or physical dependency. Unlike some stimulant laxatives, Lubiprostone does not cause the bowel to become 'addicted' to the medication for normal function. However, because it is treating a chronic condition, your symptoms of constipation or IBS-C are very likely to return once the medication is discontinued. It is always best to consult with your healthcare provider before stopping any chronic medication to ensure you have a plan for managing your symptoms. Your doctor may suggest lifestyle changes or alternative therapies.
If you miss a dose of Lubiprostone, you should take it as soon as you remember, provided it is not almost time for your next scheduled dose. If you are close to the time of your next dose, simply skip the missed one and continue with your regular schedule. Never take two doses at the same time to 'catch up,' as this significantly increases the likelihood of experiencing severe nausea and diarrhea. Maintaining a consistent routine by taking the medication with breakfast and dinner can help you remember your doses. If you frequently miss doses, consider using a pill reminder app.
Weight gain is not a recognized or common side effect of Lubiprostone. In clinical trials, there was no significant evidence that the drug affects metabolism, fat storage, or appetite in a way that would lead to weight gain. Some patients might feel a decrease in weight or 'bloating' as the medication helps clear the bowels of backed-up waste. If you experience sudden or unexplained weight gain while taking this medication, it is likely due to another factor, such as changes in diet, activity level, or another underlying health condition. You should discuss any significant weight changes with your doctor.
Lubiprostone has a low potential for drug-drug interactions because it acts locally in the gut and is not processed by the liver's cytochrome P450 system. However, certain medications like methadone may potentially reduce its effectiveness. Additionally, taking Lubiprostone with other laxatives can increase the risk of severe diarrhea and dehydration. Anticholinergic drugs may also oppose the effects of Lubiprostone by slowing down the gut. Always provide your healthcare provider with a full list of your current medications to ensure there are no conflicting treatments.
Yes, Lubiprostone is available as a generic medication. The FDA approved the first generic versions of Lubiprostone (Amitiza) in early 2021. Generic versions are required to have the same active ingredient, strength, dosage form, and route of administration as the brand-name drug. Choosing the generic version can often significantly reduce the out-of-pocket cost for patients. You should check with your pharmacist and insurance provider to see if the generic version is covered under your plan. Both the brand and generic versions require a valid prescription from a healthcare provider.